| 0 (0%) | 10-16 05:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.53 | 1-year : | 6.1 |
| Resists | First : | 4.73 | Second : | 5.23 |
| Pivot price | 4.33  |
|||
| Supports | First : | 3.94 | Second : | 3.28 |
| MAs | MA(5) : | 4.15 |
MA(20) : | 4.31 |
| MA(100) : | 5.8 |
MA(250) : | 6.79 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 16.8 |
D(3) : | 18.3 |
| RSI | RSI(14): 35.2 |
|||
| 52-week | High : | 17.37 | Low : | 0.66 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VRCA ] has closed above bottom band by 22.2%. Bollinger Bands are 60.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.16 - 4.18 | 4.18 - 4.2 |
| Low: | 3.93 - 3.96 | 3.96 - 3.99 |
| Close: | 4.05 - 4.1 | 4.1 - 4.14 |
Thu, 16 Oct 2025
Does VRCA show high probability of rebound - Weekly Trade Review & AI Forecast Swing Trade Picks - newser.com
Wed, 15 Oct 2025
What earnings revisions data tells us about VRCA - 2025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Mon, 13 Oct 2025
Verrica Pharmaceuticals stock dips after pricing $42M securities offering - MSN
Wed, 24 Sep 2025
‘One of the most competitive yet’: VRCA’s 36th annual Gold Awards of Excellence winners - constructconnect.com
Fri, 19 Sep 2025
$10M Milestone Achievement: Verrica's Molluscum Drug YCANTH Receives Landmark Japan Approval via Torii - Stock Titan
Fri, 19 Sep 2025
VRCA at Crossroads: Buy or Sell? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 9 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 43.4 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 428 (K) |
| Shares Short P.Month | 166 (K) |
| EPS | -7.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.89 |
| Profit Margin | 0 % |
| Operating Margin | 11.8 % |
| Return on Assets (ttm) | -52 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 145.3 % |
| Gross Profit (p.s.) | 0.53 |
| Sales Per Share | 1.55 |
| EBITDA (p.s.) | -3.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.53 |
| PEG Ratio | 0 |
| Price to Book value | -2.17 |
| Price to Sales | 2.63 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|